Canada markets closed

Antibe Therapeutics Inc. (ATE.TO)

Toronto - Toronto Real Time Price. Currency in CAD
Add to watchlist
0.29500.0000 (0.00%)
At close: 03:59PM EDT
Currency in CAD

Valuation Measures4

Market Cap (intraday) 15.64M
Enterprise Value -39.17M
Trailing P/E N/A
Forward P/E N/A
PEG Ratio (5 yr expected) N/A
Price/Sales (ttm)N/A
Price/Book (mrq)0.60
Enterprise Value/Revenue N/A
Enterprise Value/EBITDA 2.15

Trading Information

Stock Price History

Beta (5Y Monthly) 0.12
52-Week Change 3-45.37%
S&P500 52-Week Change 323.57%
52 Week High 31.2300
52 Week Low 30.1500
50-Day Moving Average 30.4587
200-Day Moving Average 30.6432

Share Statistics

Avg Vol (3 month) 3133.13k
Avg Vol (10 day) 3N/A
Shares Outstanding 553.01M
Implied Shares Outstanding 653.01M
Float 849.82M
% Held by Insiders 17.94%
% Held by Institutions 10.00%
Shares Short (Apr 15, 2024) 456.9k
Short Ratio (Apr 15, 2024) 40.15
Short % of Float (Apr 15, 2024) 4N/A
Short % of Shares Outstanding (Apr 15, 2024) 40.11%
Shares Short (prior month Mar 15, 2024) 44.67k

Dividends & Splits

Forward Annual Dividend Rate 4N/A
Forward Annual Dividend Yield 4N/A
Trailing Annual Dividend Rate 30.00
Trailing Annual Dividend Yield 30.00%
5 Year Average Dividend Yield 4N/A
Payout Ratio 40.00%
Dividend Date 3Dec 01, 2020
Ex-Dividend Date 4N/A
Last Split Factor 21:10
Last Split Date 3Dec 01, 2020

Financial Highlights

Fiscal Year

Fiscal Year Ends Mar 31, 2023
Most Recent Quarter (mrq)Dec 31, 2023

Profitability

Profit Margin 0.00%
Operating Margin (ttm)0.00%

Management Effectiveness

Return on Assets (ttm)-19.13%
Return on Equity (ttm)-52.72%

Income Statement

Revenue (ttm)N/A
Revenue Per Share (ttm)N/A
Quarterly Revenue Growth (yoy)N/A
Gross Profit (ttm)N/A
EBITDA N/A
Net Income Avi to Common (ttm)-18.24M
Diluted EPS (ttm)-0.3500
Quarterly Earnings Growth (yoy)N/A

Balance Sheet

Total Cash (mrq)24.91M
Total Cash Per Share (mrq)0.47
Total Debt (mrq)N/A
Total Debt/Equity (mrq)N/A
Current Ratio (mrq)10.06
Book Value Per Share (mrq)0.49

Cash Flow Statement

Operating Cash Flow (ttm)-18.25M
Levered Free Cash Flow (ttm)-12.28M